Cover Image
市場調查報告書

腦白質失養症 - 開發中產品分析

Leukodystrophies - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 321934
出版日期 內容資訊 英文 41 Pages
訂單完成後即時交付
價格
Back to Top
腦白質失養症 - 開發中產品分析 Leukodystrophies - Pipeline Review, H2 2015
出版日期: 2015年09月09日 內容資訊: 英文 41 Pages
簡介

腦白質失養症是影響中樞神經髓磷脂的遺傳性疾病,會出現肌肉緊張、發話、視力,智力,理解,身體的動作等緩慢的變化。是由於X染色體或常染色體的劣性遺傳。

本報告提供腦白質失養症治療藥的開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

腦白質失養症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 臨床階段的產品
  • 初期階段的產品

開發中的產品:各企業

治療藥的開發企業

  • ArmaGen Technologies, Inc.
  • Fate Therapeutics, Inc.
  • GlaxoSmithKline plc
  • Phenomenome Discoveries, Inc.
  • ReGenX Biosciences, LLC
  • Shire Plc

治療藥的評估

  • 單獨療法的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AGT-183
  • FT-1050
  • Gene Therapy to Activate Arylsulfatase A for Metachromatic Leukodystrophy
  • GSK-2696274
  • PPI-1011
  • SHP-611

最新的開發平台資訊

開發暫停中的計劃

開發中止的產品

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7142IDB

Summary

Global Markets Direct's, 'Leukodystrophies - Pipeline Review, H2 2015', provides an overview of the Leukodystrophies's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Leukodystrophies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leukodystrophies and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Leukodystrophies
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Leukodystrophies and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Leukodystrophies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Leukodystrophies pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Leukodystrophies
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Leukodystrophies pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Leukodystrophies Overview
  • Therapeutics Development
    • Pipeline Products for Leukodystrophies - Overview
    • Pipeline Products for Leukodystrophies - Comparative Analysis
  • Leukodystrophies - Therapeutics under Development by Companies
  • Leukodystrophies - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Leukodystrophies - Products under Development by Companies
  • Leukodystrophies - Companies Involved in Therapeutics Development
    • ArmaGen Technologies, Inc.
    • Fate Therapeutics, Inc.
    • GlaxoSmithKline Plc
    • Phenomenome Discoveries, Inc.
    • RegenxBio Inc.
    • Shire Plc
  • Leukodystrophies - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AGT-183 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FT-1050 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate Arylsulfatase A for Metachromatic Leukodystrophy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GSK-2696274 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PPI-1011 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SHP-611 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Leukodystrophies - Recent Pipeline Updates
  • Leukodystrophies - Dormant Projects
  • Leukodystrophies - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Leukodystrophies, H2 2015
  • Number of Products under Development for Leukodystrophies - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Leukodystrophies - Pipeline by ArmaGen Technologies, Inc., H2 2015
  • Leukodystrophies - Pipeline by Fate Therapeutics, Inc., H2 2015
  • Leukodystrophies - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Leukodystrophies - Pipeline by Phenomenome Discoveries, Inc., H2 2015
  • Leukodystrophies - Pipeline by RegenxBio Inc., H2 2015
  • Leukodystrophies - Pipeline by Shire Plc, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Leukodystrophies Therapeutics - Recent Pipeline Updates, H2 2015
  • Leukodystrophies - Dormant Projects, H2 2015
  • Leukodystrophies - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Leukodystrophies, H2 2015
  • Number of Products under Development for Leukodystrophies - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top